Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you offer ultrahypofractionated 5 fraction breast radiation to a patient with lupus?
Answer from: Radiation Oncologist at Community Practice
Favor partial breast over whole breast if feasible.APBI or IMPORT LOW volume and FAST-Forward dose of 26 in 5.
Sign in or Register to read more
17734
Related Questions
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
What are your top takeaways in Breast Cancer from ESMO 2024?
What is the earliest you would start postmastectomy radiation after adjuvant chemotherapy for a patient with breast cancer?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?